Bomtabegagene bavoparvovec

沃哌泊基

Report date: 2023/10/26 16:19:41

Base Information

Drug NameBomtabegagene bavoparvovec
Drug Alias NameAAV9-GLB1AXO-AAV-GM1
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector > AAV9 vector
Mechanisms of ActionBeta-galactosidase modulatorsGene transference
TargetsBeta-galactosidase
Therapy Area/IndicationsGangliosidoses
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Of Massachusetts Medical School
China Registration ClassN/A

Develop Information

Active CompaniesNational Human Genome Research InstituteSio Gene Therapies Inc
Inactive CompaniesN/A
Active IndicationsGangliosidoses
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A